Evidence map›Paper›PMID 24981332›Full record

ArticleCell host & microbe2014

Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements.

Katherine J L Jackson, Yi Liu, Krishna M Roskin, Jacob Glanville, Ramona A Hoh, Katie Seo, Eleanor L Marshall, Thaddeus C Gurley, M Anthony Moody, Barton F Haynes and 15 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cell host & microbe, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01827462 (Immune Senescence in the Elderly), which is not on this map. Cited by 156 papers.

0numbers the graph read from it
0cells of the map it votes in
156citing papers in PubMed
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01827462 phase4completednot on this map

Immune Senescence in the Elderly: Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages

TypeinterventionalSponsorStanford UniversityRan2007 to 2017Enrolled136ConditionsInfluenzaArmsTrivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
3 · Its place in the literature

Who cites it

156 citing papers in PubMed, 261 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Systems biology of B cells in COVID-19.Seminars in immunology · 2024
    Review

96 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 2 countries.

Katherine J L JacksonDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA; School of Biotechnology and Biomolecular Science, University of New South Wales, Sydney, NSW 2052, Australia.
Yi LiuBiomedical Informatics Training Program, Stanford University, Stanford, CA 94305, USA.
Krishna M RoskinDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Jacob GlanvilleDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Ramona A HohDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Katie SeoDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Eleanor L MarshallDepartment of Genetics, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Thaddeus C GurleyDuke Human Vaccine Institute, Durham, NC 27710, USA.
M Anthony MoodyDuke Human Vaccine Institute, Durham, NC 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Durham, NC 27710, USA.
Emmanuel B WalterDuke Human Vaccine Institute, Durham, NC 27710, USA.
Hua-Xin LiaoDuke Human Vaccine Institute, Durham, NC 27710, USA.
Randy A AlbrechtDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Javier Chaparro-RiggersProtein Engineering, Rinat-Pfizer Inc., South San Francisco, CA 94080, USA.
Arvind RajpalProtein Engineering, Rinat-Pfizer Inc., South San Francisco, CA 94080, USA.
Jaume PonsProtein Engineering, Rinat-Pfizer Inc., South San Francisco, CA 94080, USA.
Birgitte B Simen454 Life Sciences Corporation, a Roche Company, Branford, CT 06405, USA.
Bozena Hanczaruk454 Life Sciences Corporation, a Roche Company, Branford, CT 06405, USA.
Cornelia L DekkerDepartment of Pediatrics, Stanford University, Stanford, CA 94305, USA.
Jonathan LasersonDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA.
Daphne KollerDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA.
Mark M DavisDepartment of Microbiology and Immunology and Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute.
Andrew Z FireDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Genetics, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Scott D BoydDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: sboyd1@stanford.edu.
Stanford University · USPfizer (United States) · USEnzo Life Sciences (United States) · USIcahn School of Medicine at Mount Sinai · USHoward Hughes Medical Institute · USUNSW Sydney · AU

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI CRUMP, JOHN ANDREW · 2006 to 2011
$290.5M
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Virology CoreP01AI089618 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Jiwon Lee · 2011 to 2026
$40.0M
Vaccination and infection: indicators of immunological health and responsivenessU19AI090019 · NIAID · STANFORD UNIVERSITY · PI DAVIS, MARK MORRIS · 2010 to 2015
$17.3M
Vaccine Induced Activation of T Follicular Helper Cell SubsetsU19AI089987 · NIAID · BAYLOR RESEARCH INSTITUTE · PI PASCUAL, MARIA VIRGINIA · 2010 to 2015
$17.0M
NIAID NIH HHS 1U19AI089987NIAID NIH HHS AI0678501NIAID NIH HHS P01 AI089618NIAID NIH HHS P01AI089618NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI067854NIAID NIH HHS U19AI067854NIAID NIH HHS U19 AI089987NIAID NIH HHS U19 AI090019NIAID NIH HHS U19AI090019
6 · The paper itself

Abstract

B cells produce a diverse antibody repertoire by undergoing gene rearrangements. Pathogen exposure induces the clonal expansion of B cells expressing antibodies that can bind the infectious agent. To assess human B cell responses to trivalent seasonal influenza and monovalent pandemic H1N1 vaccination, we sequenced gene rearrangements encoding the immunoglobulin heavy chain, a major determinant of epitope recognition. The magnitude of B cell clonal expansions correlates with an individual's secreted antibody response to the vaccine, and the expanded clones are enriched with those expressing influenza-specific monoclonal antibodies. Additionally, B cell responses to pandemic influenza H1N1 vaccination and infection in different people show a prominent family of convergent antibody heavy chain gene rearrangements specific to influenza antigens. These results indicate that microbes can induce specific signatures of immunoglobulin gene rearrangements and that pathogen exposure can potentially be assessed from B cell repertoires.

Indexed as

Gene Rearrangement, B-LymphocyteAntibodies, ViralAntibody FormationHumansInfluenza, HumanInfluenza VaccinesAntibodies, ViralInfluenza Vaccines

Identifiers

PMID24981332
PMCPMC4158033
OpenAlexW2038873256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.